Purpose: To investigate the feasibility, effectiveness and acceptability of using prosthetic occluding contact lenses (OCLs) to treat moderate amblyopia in adults and of the role of the multifocal visual evoked potential (mfVEP) as a predictor of postamblyopic therapy. Methods: A comparative, prospective, interventional, case series pilot study with amblyopic adults (mean age: 40 years, range 20-50 years) allocated into two intervention groups: eye patching and OCL. The primary outcome variable was logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), and secondary outcomes were mfVEP amplitude and latency and patients' health-related quality of life National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Results: Significant improvements in pre-to postamblyopic therapy BCVA were seen at 1.5 months in the OCL group [0.29 logMAR, 95% confidence interval (CI): 0.10-0.47 versus 0.11 logMAR, 95% CI: 0.02-0.19; p < 0.001] and eye patching group (0.29 logMAR, 95% CI: 0.17-0.40 versus 0.18 logMAR, 95% CI: 0.12-0.23; p < 0.01). Post-treatment BCVA was inversely related to age (R: 0.009, 95% CI: À0.02 to À0.001; p = 0.04) and the presence of strabismus (R: À0.3, 95% CI: À0.434 to À0.17; p = 0.001). No significant changes in the number and size of the abnormal mfVEP amplitude and latency defects were observed after occlusion. The NEI VFQ-25 composite score showed significant improvement in the OCL users at 12 months compared to eye patching. Conclusion: Significant vision improvement can be achieved, making occlusion with OCLs an effective and more acceptable therapy for adults with amblyopia.
Introduction
There is comprehensive evidence to suggest that the central nervous system retains compelling neural plasticity in adulthood, and that this may be applied to enhance visual function in older children and adults with amblyopia (Thompson et al. 2008; Tsirlin et al. 2015; Prins et al. 2016) . Current results from both clinical trials and animal experimental models endorse this hypothesis, exposing a hitherto unexpected potential for promoting visual recovery even in older ages (Von Noorden 1985; Levi & Li 2009a; Kiorpes & McKee 1999; Von Noorden & Crawford 1979) .
The American Academy of Ophthalmology's preferred practices for amblyopia suggest treatment of children up to 10 years old (American Academy of Ophthalmology 2002). However, despite successful treatment using occlusion therapy, a large number of children still show amblyopia in later life due to several factors, such as failure of detection, visual acuity (VA) loss following disruption of treatment, lack of response to the original treatment or partial treatment of the amblyopia (American Academy of Ophthalmology 2002; Rahi et al. 2006; Stewart et al. 2004a) .
The established concept that a critical period exists for the development of amblyopia and disruption of vision has usually led to the hypothesis that this is similar to the period of time during which amblyopia can be treated and vision improved (Gilbert & Wiesel 1992; Baker et al. 2007) . While amblyopia can often be corrected when treated early, current treatment is not usually undertaken in amblyopic adults in the clinical setting. Although no large, controlled, clinical trials of treatment of amblyopic adults have been published, several case series show that amblyopia in adults can be improved and VA spontaneously augmented in the presence of visual loss in the fellow eye (Wick et al. 1992; EI Mallah et al. 2000) .
Standard clinical treatment of amblyopia generally means penalizing or occluding the non-amblyopic eye using inexpensive, complete occlusion that is readily reversible by removing the patch. However, prolonged eye patching is not especially tolerated in adults because of the visual demands of social and work life (Wick et al. 1992) . Compliance in older children and adults can be a significant problem with patching therapy, so there is a need for alternative treatment modalities (Webber et al. 2008) . As a potential alternative to amblyopia occlusive treatment, prosthetic OCLs can be a cost-effective therapeutic option. Several studies have shown the efficacy of using extended wear OCLs to treat amblyopic children, suggesting that prosthetic OCLs are a viable alternative to eye patching and other forms of penalization therapy (Eustis & Chamberlain 1996; Tsubota & Yamada 1994; Joslin et al. 2002) .
Treatments for amblyopic adults should be aimed at building up cortical plasticity by targeting those components that actively restrain adult plasticity, or by developing endogenous susceptible factors. Under these favourable conditions, circuit rewiring may be facilitated in the adult brain, inducing rehabilitation from amblyopia. Novel therapies -like perceptual learning, video games and dichoptic training -that improve VA and/or stereoacuity in adult amblyopia have been recently proposed. All these new treatments should increase the interest in offering more engaging therapeutic choices for treating amblyopia in adults (Malik et al. 1975; Mohan et al. 2004; Wu & Hunter 2006; Chen et al. 2008; Thompson et al. 2008) .
Visual improvement has been seen to be proportional to the increase in the pattern visual evoked potential (VEP) P100 amplitude in children with anisometropic amblyopes treated with occlusion therapy (Oner et al. 2004; Parisi et al. 2010) . Moreover, sweep VEP or pattern VEP has been shown to be related to the Snellen VA changes after amblyopia treatment in children. Sweep acuity and P100 latency are good predictors of VA after treatment (Ridder & Rouse 2007; Chung et al. 2008; Ridder et al. 2012; De Mendonc ßa et al. 2013) . In this study, we also wanted to analyse the role of the mfVEP responses as a predictor of occlusion therapy for adult amblyopic patients.
The main purpose of this study was to investigate the feasibility and effectiveness of using OCLs to treat moderate amblyopia in adults and the role of the mfVEP as a predictor of occlusion therapy. The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) (Mangione et al. 2001 ) was used to assess vision-related quality of life and self-reported visual functions for this therapy.
Materials and Methods

Study population
Ten subjects (five men and five women; mean age: 40 years, range: 20-50 years) with monocular anisometropic and/or strabismic amblyopia were evaluated. Inclusion criteria were the following: (i) BCVA of 0.10 logMAR or higher in the amblyopic eye; (ii) the presence of anisometropia or strabismus (or both) and age >18 years; and (iii) interocular difference in VA of at least 0.20 logMAR. Anisometropia was described as a difference of two or more dioptres in spherical equivalence between both eyes. The major exclusion criterion was the presence of any comorbid ocular disease (retinal damage, cataract, glaucoma) as the cause of the reduced VA. This study protocol was approved by the Institutional Review Board and complied with the precepts of the Declaration of Helsinki. All study subjects gave their informed consent. Data were kept in accordance with Spain's Data Protection Law (No 15/1999) to protect patient confidentiality.
Study protocol
The study is a comparative, prospective, interventional, case series, pilot study. Individuals were randomly assigned to two groups: five patients used adhesive ocular patches (Opticlude Ò , Nexcare Ò , 3M, St.Louis, MN, USA) and the other five used customized prosthetic OCLs in addition to wearing spectacles correcting the full refractive error. The OCLs were made of pHema (KV38; Servilens, Granada, Spain), with an oxygen transmissibility (Dk/t) value of 12 and were tinted to order with an iris print according to the patient's iris colour. They had a single layer of iris print density, no underprint and an opaque pupil size of 5 mm. According to the OCL maker, the tinted iris allowed 2-3% light transmittance.
All subjects received detailed instructions on how to care for the OCLs and were instructed to remove them at any sign of ocular irritation. The occlusion regime was prescribed for at least 4 hr per day, as per Pediatric Eye Disease Investigator Group (PEDIG) guidelines for moderate amblyopia (Scheiman et al. 2008) and for a total duration of 12 months. The primary outcome variable was distance logMAR BCVA, and secondary outcomes were mfVEP amplitude/latency and survey NEI VFQ-25 vision-specific quality of life changes after the intervention.
During enrolment and at each of the scheduled visits, all subjects underwent a thorough eye examination that included: (i) logMAR BCVA, carried out with an Early Treatment Diabetic Retinopathy Study (ETDRS) crowded VA chart at 5 m; (ii) colour vision, tested using pseudoisochromatic plates; (iii) pupil size, measured in ambient light with a Rosenbaum gauge; (iv) slit-lamp biomicroscopy and a dilated fundus examination; (v) manifest and cycloplegic refraction; (vi) ocular deviation, assessed with the alternate prism cover-test; (vii) stereopsis, screened with the TNO test; (viii) binocular single vision, tested with the Worth 4-dot test at a distance of 40 cm, and foveal fixation, tested with a visuscope.
Visual fields were evaluated at baseline and at follow-up after 12 months with the Humphrey Field Analyzer 750 (Carl Zeiss, Inc., Dublin, US) using the Swedish Interactive Threshold Algorithm (SITA) standard central 24-2 protocol. The stimulus was a Goldman size III with a background luminance of 31 apostlibs. The criteria for visual field assessment were fixation losses lower than 20% and a percentage of false negatives and positives lower than 33% and 20%, respectively. Visual fields not complying with these principles were dismissed.
Optical coherence tomography (OCT) was performed at baseline with a Spectral Domain OCT Cirrus (Carl Zeiss). First, we selected an optic disc cube (200 9 200) centred on the optic disc to measure the retinal nerve fibre layer thickness (RNFLT). Then, we used a macular cube (512 9 128) centred on the fovea to measure the macular volume (MV).
A vision-specific health-related quality of life (HRQL) questionnaire (NEI VFQ-25) was used to evaluate the impact of amblyopia on visual function, self-esteem and social communication at baseline and after treatment (Mangione et al. 2001) .
Multifocal visual evoked potentials (mfVEP) were recorded at baseline and at 6 and 12 months after treatment using the VERIS 6.1 (Electro-Diagnostic Imaging, San Mateo, USA) mfVEP software, as detailed by us elsewhere (Blanco et al. 2014) . Briefly, we used a scaled dartboard stimulus (44.5°in diameter) accommodating sixty sectors, each with sixteen alternating checks, and a Michelson contrast of about 99%. The dartboard pattern reversed according to a pseudorandom m-sequence at a frame rate of 75 Hz. The sectors were cortically scaled to activate similar areas of the visual cortex (Sutter 2001) . Three channels were obtained. For the midline channel, the electrodes were placed four centimetres above the inion (active) and at the inion (reference). The active electrodes for the other two channels were located one centimetre above and four centimetres lateral to the inion on both sides. The impedance was always below 5 K. Records were amplified with frequency cut-offs set at 3 and 100 Hz and sampled at 1200 Hz (preamplifier P511J; Grass, Rockland, MA, USA).
Fourteen-minute recordings were obtained for each eye. The recordings were averaged, and second-order kernel best-channel responses were extracted. All response analyses were performed with programs developed in MATLAB (Mathworks Inc., Natick, MA, USA) (Hood et al. 2002) . Monocular and interocular latencies were measured as the temporal shift producing the best cross-correlation value between a template based on control eyes and the corresponding responses of the subject's eye. Interocular amplitude differences were obtained by calculating the interocular ratio logarithm at each location. To evaluate the mfVEP and Humphrey visual field (HVF) total deviation results, cluster effects were analysed. A defective cluster was defined as having either three or more contiguous points at p < 0.05, with at least one point at p < 0.01, or two or more contiguous points at p < 0.01.
Statistical analysis
We used SPSS version 16.0 software (IBM, New York, USA) for all statistical analyses. All data were expressed as the mean and standard error of the mean. Fisher's exact test or the chi-square test was used to evaluate differences in proportions as required. If the normal distribution could be assumed, differences of two means were assessed using Student's t-test while, if normality was not valid, they were assessed using the non-parametric Mann-Whitney Utest. Best-corrected visual acuity (BCVA) changes were evaluated by repeated-measures analysis of variance and the Bonferroni multiple comparisons post-test. Linear regression analysis was used to identify predictive variables of BCVA improvement. A p-value <0.05 was considered statistically significant.
Results
Characteristics of the study population Table 1 summarizes the baseline demographic and ophthalmological characteristics of the amblyopic study cohort. Amblyopia was due to anisometropia in seven subjects, to strabismus in two, and to both anisometropia and strabismus in one subject. Three subjects had undergone earlier therapy with surgery and/or botulinum toxin. Steady foveal fixation was seen in all amblyopic eyes. None had either eccentric fixation or unsteady foveal. Seven (70%) subjects presented stereopsis of >60 min of arc as baseline, while fusion was present in eight (80%) subjects. At baseline, the OCT did not show any significant differences between the amblyopic and non-amblyopic fellow retinas on the average RNFLT (94.83 AE 11.06 lm versus 97.6 AE 9.59 lm; p = 0. ; p = 0.45).
Visual performance of the amblyopic eye
In the OCL group (Fig. 1) , there were significant differences between the baseline BCVA (0.29 logMAR; 95% CI: 0.10-0.47) and at 1.5 months posttherapy (0.11 logMAR; 95% CI: 0.02-0.19; p < 0.001). However, there were no differences between the BCVA reached at 3 months (0.10 logMAR; 95% CI: 0.02-0.17), 6 months (0.08 logMAR; 95% CI: 0.01-0.15) or 12 months (0.08 logMAR; 95% CI: 0.01-0.15; p > 0.05). Likewise, in the eye patching group, there were significant differences between baseline BCVA (0.29 logMAR; 95% CI: 0.17-0.40) and follow-up at 1.5 months (0.18 logMAR; 95% CI: 0.12-0.23; p < 0.01). However, there were not any further differences between the BCVA achieved at 3 months (0.15 logMAR logMAR; 95% CI: 0.06-0.23), 6 months (0.12 logMAR; 95% CI: 0.01-0.23) or 12 months (0.09 logMAR; 95% CI: 0.03-0.21; p > 0.05).
There was a good correlation between BCVA change and baseline BCVA of the amblyopic eye (r 2 = 0.57; p = 0.001; Fig. 2 Contact lens users showed higher quality of life scores as measured with the NEI VFQ-25 (Fig. 3) . We found significant differences between the NEI VFQ-25 composite score at baseline (86.8; 95% CI: 90.4-97.4) and at 12 months (92.6; 95% CI: 83.3-101.9; p = 0.03) in the OCL group. On the other hand, the baseline NEI VFQ-25 composite score (94.2; 95% CI: 78.1-86.1) was not significantly different after eye patching (95.4; 95% CI: 92-98.7; p = 0.08). The patching group had a higher baseline level on the NEI VFQ-25 than the OCL group, although the difference was not significant. However, there may be ceiling effects that limited the ability of the patching group to improve.
All subjects underwent regular OCL checks, and no significant ocular problems were reported related to OCL use. All patients reported very good compliance, especially since their BCVA improved quickly in their first weeks of therapy.
At baseline, HVF mean deviation and pattern standard deviation showed significant differences between the amblyopic and non-amblyopic fellow eyes (À2.87 AE 1.78 versus À1.51 AE 2.54; p < 0.05) and (2.01 AE 0.88 versus 1.24 AE 1.38; p < 0.05), respectively. No significant changes in the number and size of the abnormal HVF cluster defects were observed in the amblyopic eyes in either group after occlusion at 6 or 12 months (p = 0.64).
Electrophysiological assessment of the visual pathway
Changes detected by mfVEP in amblyopic eyes' visual function are shown in Table 2 . At baseline, mfVEP amplitude and latency responses (abnormal cluster defects) were detected using combined interocular and monocular probability analysis in both the amblyopic (100%) and non-amblyopic eyes (20%; p < 0.001) in the OCL group. No significant changes in the number and size of the abnormal mfVEP amplitude and latency cluster defects were observed after 6 or 12 months of occlusion (p = 0.76). On the other hand, in the eye patching group, abnormal mfVEP amplitude and latency responses were observed in both the amblyopic (100%) and nonamblyopic eyes (60%; p < 0.001) at baseline. No significant changes in the number and size of the abnormal mfVEP amplitude and latency cluster defects were observed after occlusion at 6 or 12 months (p = 0.88). The intraclass correlation coefficient (r) (i) between the pretherapy mfVEP latency and the post-therapy BCVA was 0.11. Representative mfVEP probability plots from one of the patients (#5) at baseline and at follow-up after 12 months are illustrated in Fig. 4 . The results of linear regression analysis of the predictive variables of BCVA improvement with both OCLs and eye patching are shown in Table 3 . In the univariate linear regression analysis, post-treatment BCVA was inversely related to age (R: 0.009; 95% CI: À0.02 to À0.001; p = 0.04) and the presence of strabismus (R: À0.3; 95% CI: À0.43 to À0.17; p = 0.001). Multifocal visual evoked potential (mfVEP) amplitudes and latency did not show any statistically predictive value.
Discussion
Our preliminary results suggest that sufficient vision penalization and a substantial degree of visual plasticity can be achieved to make occlusion with prosthetic OCLs a cost-effective and sustainable therapy in adults with amblyopia. The use of OCLs may add significant value when treating amblyopic adults in clinical settings, offering significant potential for cost-effectiveness, improved VA, cosmesis and compliance.
There is considerable evidence to support the amblyopic visual system's potential to improve after the critical period of visual development. Thus, the accepted clinical practice whereby rehabilitation therapy is generally not offered to amblyopic adults may need to be reconsidered (Levi et al. 1997; Barrett et al. 2004; Polat et al. 2004 ). Conventional treatment of amblyopia, although still widely used and of great value in younger children, is currently being updated by the findings of studies into the efficacy of other therapy modalities tested in older children and adults. Because of very poor compliance, negative psychosocial consequences and a potential reduction in binocularity, eye patching is generally not done in adults (Webber et al. 2008 ). It has been described that for amblyopes of any age with a VA of 20/ 60 or higher, the probability of the treatment being successful can be very high (better than 70%) (Flynn et al. 1999) . This is relevant, because the prevalence of VA in most amblyopic adults is between 20/30 and 20/60 (Mckee et al. 2003) . So, for moderate amblyopia with a VA of between 20/40 and 20/60, an improvement by a factor of two or more would readily eliminate the amblyopia and may also allow restoration of some binocular function (Li et al. 2004 ). In agreement with other studies, the dose response rate for OCL occlusion in our study cohort was about 0.1 log unit for every 120 hr of occlusion, and the therapeutic efficacy range was more than two log-MAR lines, reaching a dose-response plateau after 200 hr (Stewart et al. 2004a (Stewart et al. ,b, 2005 Moseley et al. 2006) .
Any patient who can readily adapt to standard contact lens wear could also use these tinted lenses, provided the lenses are well maintained. Nowadays, OCLs are commercially available in all the parameters of clear lenses. Occluding contact lense cost has gone down significantly in recent years and is now below USD 100 in our context. Newer micro-pigmentation techniques also allow for very detailed customization, like different opaque pupil sizes (3-5 mm), light or dark underprints, single or double iris prints and variable iris diameters. We can customize the degree of penalization while potentially leaving the peripheral fusion intact by changing the size of the opaque pupil or by adding underprints (Collins et al. 2008; Kishimoto et al. 2014) . Although the risks of using OCLs are admissible when compared to eye patching, the need for a short-duration therapy and the lack of ocular complications in the occluded eye found in our study are reassuring.
Health-related quality of life is a clinically recognized parameter to assess the quality of life dysfunction related to amblyopia and to help quantify the outcome of clinical intervention. In this regard, the NEI VFQ-25 survey has been shown to be a valid and reliable tool for measuring vision-specific quality of life parameters (Hirneiss et al. 2010) . Patients using OCLs presented significantly higher quality of life scores than those using patching, probably because the use of OCLs was more easily accepted and it did not interfere with their daily social and work lives. Occluding contact lenses (OCLs) are more cosmetically tolerable and appealing than other amblyopia treatment methods, and all these factors may positively increase compliance in occlusion therapy. Following the concept of quality-adjusted life years (QALYs), treatment for amblyopia in adults is likely to be very cost-effective and may provide a relatively small but longlasting improvement in HRQL. According to various studies, the incremental cost-effectiveness ratio (ICER) of treatment for amblyopia ranges from USD 2053 to USD 2509 per QALY (Membreno et al. 2002; K€ onig & Barry 2004) . Moreover, in a recent cost-utility studies review, the ICER of treatment for amblyopia was more significant than that of other common health-care interventions, where the median cost per QALY has been shown to be USD 12 000 (Chapman et al. 2000) . Previous studies using either conventional or multifocal VEP have reported abnormal visual scotomas in response latencies and amplitudes in the amblyopic and fellow normal eye in adult amblyopes (Yu et al. 1998; Greenstein et al. 2008; P erez-Rico et al. 2015) , as we have reported here. However, mfVEP latency or amplitude was not significantly associated with visual recovery after occlusion therapy and no changes in the number and size of visual scotomas were readily observed, although further research with a larger cohort is warranted.
Based on the preliminary findings of this study and on the published literature, initial short-term therapy with OCLs followed by perceptual learning activities could be the best choice for most adults. If perceptual learning can significantly raise the effectiveness and reduce the duration of OCL wear, perceptual learning would be a greatly advantageous clinical option in adults (Polat et al. 2004; Zhou et al. 2006; Levi & Li 2009b ). However, perceptual learning exercises are not immediately offered as a therapeutic option in many clinical settings because they usually require a significant number of appointments and can be a costly clinical process. The results of perceptual learning in amblyopic subjects have been shown to be rather longlasting. However, as during perceptual learning experiments, the preferred eyes of amblyopic subjects are usually patched while they do the assignment, at least some of the gain may be the outcome of eye patching by itself (Repka et al. 2003; Astle et al. 2011) .
Design limitations of this study were its relatively small sample size and that the examiners were not masked to the treatment groups. A much larger sample size would be necessary for future studies in order to validate this occlusion strategy in a randomized controlled trial, and a similar methodology should be used to determine the benefit of combining OCL occlusion therapy with perceptual learning. A critical issue to address in amblyopic adults is the potential regression of VA, as even a small degradation in VA could potentially The saturated colour indicates points with p < 0.01, and the desaturated colour indicates points with p < 0.05. The interocular amplitude probability plot shows a similar cluster of abnormal points in the paracentral area of the RE at baseline and at 12 months post-therapy. On the monocular and interocular latency probability plot, there is also a small abnormal central cluster of abnormal points in the RE. e352 have significant effects on visual standards (Repka et al. 2005; Nilsson et al. 2007) . In summary, this study provides a novel strategy for treating visual neurorehabilitation in adults with amblyopia, suggesting that, using OCLs, visual penalization can be promptly achieved to therapeutic levels. This alternative treatment can be a costeffective occlusion option that many amblyopic adults will find more cosmetically appropriate than other amblyopia treatment methods. Occluding contact lenses (OCLs) treatment of amblyopia in adults should be examined in independent cohorts and further prospective studies.
